# Gensciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gensciences

- Industry: Biotechnology
- Headquarters: Nantong, China
- Website: www.gensciences.com
- Latest round: Series B (Mar 4, 2021)
- Investors on record: 10

## About

Founded in 2019 and based in Nantong, China, Gensciences is a biopharmaceutical company that focuses on the research and development of innovative drugs for hemophilia. It currently has 61 patents in the filing and granted, with an R&D team of 150 members. Yali Wang, the chairman of the company, graduated from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, with 30 years of experience in drug research and development. It has R&D centers in Beijing and Zhengzhou, as well as production bases and marketing branches in Shanghai. In November 2023, it received FDA IND approval for the recombinant factor VIII product. In June 2024, Gensciences closed a strategic investment.

Gensciences mainly engages in the research and development of recombinant protein-based innovative drugs and related products. The company set up a bio-innovative drug development system and multiple technology platforms, which can meet the product development of cell culture, microbial fermentation, and other expression systems, covering fusion proteins, protein modification, and other technologies. It currently has 4 innovative drugs that entered clinical development, which are FRSW107, FRSW117, SS109, and SS327. Products can be used in hemophilia, metabolic diseases, and antitumor areas.

The company generates revenue by providing recombinant protein-based innovative drugs and related products.

In the future, the company will continue to develop bio-innovative drugs in the fields of coagulation and metabolic diseases.

## Funding rounds

- Series B, Mar 4, 2021 — IDG Capital, New Alliance Capital, Huarong Rongde Asset Management, Efung Capital, Haitong New Venture Capital, Huaige Capital
- Series A, May 18, 2020 — IDG Capital, Cowin Capital, New Alliance Capital, Tunlan Investment, Jinsheng Capital, Huaige Capital, New Intelligence Investment

## Investors

- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series A, Series B
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series A
- New Alliance Capital (https://capitalatlas.ai/funds/new-alliance-capital) — Series A, Series B
- Tunlan Investment (https://capitalatlas.ai/funds/tunlan-investment) — Series A
- Jinsheng Capital (https://capitalatlas.ai/funds/jinsheng-capital) — Series A
- Huaige Capital (https://capitalatlas.ai/funds/huaige-capital) — Series A, Series B
- New Intelligence Investment (https://capitalatlas.ai/funds/new-intelligence-investment) — Series A
- Huarong Rongde Asset Management — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Haitong New Venture Capital (https://capitalatlas.ai/funds/haitong-new-venture-capital) — Series B